Table 3.
siRNA employment in pancreatic cancer.
| Target mRNA | Delivery System | Tumor Model | Ref. |
|---|---|---|---|
| NGF * | Gold nanoparticles | Panc-1 cell line; mouse subcutaneous model of pancreatic cancer; orthotopic patient-derived xenograft mouse model |
Lei et al. [54] |
| KRASG12D * | Exosome | Panc-1 cell line; orthotopic mouse model |
Kamerkar et al. [55] |
| PD-L1 * | PLGA | orthotopic model humanized mouse model | Jung et al. [56] |
| PLK1 * | Polymer | KPC8060 cell line; orthotopic syngenic mouse model (KPC8060); xenograft mouse model (S2-‘13) |
Tang et al. [57] |
| FARSA * | Lipofectamine and porous silicon nanoparticles | SW1990 and Panc-1 cell lines; orthotopic patient-derived xenograft mouse model |
Yuan et al. [58] |
* NGF: nerve growth factors; KRASG12D: Kirsten rat sarcoma virus mutation G12D; Bcl-2: PD-L1: Programmed death-ligand 1; PLGA: copolymer of polylactic acid and polyglycolic acid; PLK1: Polo-like kinase 1; FARSA: Phenylalanyl-TRNA Synthetase Subunit Alpha.